{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:53:49Z","timestamp":1785902029969,"version":"3.56.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011852","name":"Paracelsus Medical University","doi-asserted-by":"publisher","award":["2023-UP-007-Dorfer"],"award-info":[{"award-number":["2023-UP-007-Dorfer"]}],"id":[{"id":"10.13039\/501100011852","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002825","name":"Dystrophic Epidermolysis Bullosa Research Association of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"FWF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019725","name":"DEBRA Austria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jid.2025.12.010","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:02:20Z","timestamp":1766188940000},"page":"1978-1988.e17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Transcriptome-guided drug repurposing identifies selumetinib for an aggressive epithelial cancer"],"prefix":"10.1016","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8286-9620","authenticated-orcid":false,"given":"Sonja","family":"Dorfer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0590-3877","authenticated-orcid":false,"given":"Roland","family":"Zauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8232-5068","authenticated-orcid":false,"given":"Christina","family":"Guttmann-Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7546-3438","authenticated-orcid":false,"given":"Victoria","family":"Reichl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2001-4886","authenticated-orcid":false,"given":"Michael","family":"Ablinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Gruner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8305-6135","authenticated-orcid":false,"given":"Julia I.","family":"Hummel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8558-9031","authenticated-orcid":false,"given":"Josefina","family":"Pi\u00f1\u00f3n Hofbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6285-1789","authenticated-orcid":false,"given":"Ulrich","family":"Koller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7470-7277","authenticated-orcid":false,"given":"Iris K.","family":"Gratz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6085-9170","authenticated-orcid":false,"given":"Johann W.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8705-3890","authenticated-orcid":false,"given":"Verena","family":"Wally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2025.12.010_bib1","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1158\/1078-0432.CCR-18-2661","article-title":"Identification of rigosertib for the treatment of recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma","volume":"25","author":"Atanasova","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jid.2025.12.010_bib2","first-page":"515","article-title":"Consensus recommendations on management of selumetinib-associated adverse events in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas","volume":"11","author":"Azizi","year":"2024","journal-title":"Neurooncol Pract"},{"key":"10.1016\/j.jid.2025.12.010_bib3","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jid.2025.12.010_bib4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10637-024-01428-0","article-title":"A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors","volume":"42","author":"Ch\u00e9nard-Poirier","year":"2024","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jid.2025.12.010_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aas9668","article-title":"APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa","volume":"10","author":"Cho","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jid.2025.12.010_bib6","doi-asserted-by":"crossref","first-page":"5707","DOI":"10.3390\/ijms20225707","article-title":"Epidermolysis bullosa-associated squamous cell carcinoma: from pathogenesis to therapeutic perspectives","volume":"20","author":"Condorelli","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2025.12.010_bib7","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/bjd.19421","article-title":"Heterogeneous addiction to transforming growth factor-beta signalling in recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell carcinoma","volume":"184","author":"Dayal","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2025.12.010_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11912-020-01008-4","article-title":"Tumor and systemic immunomodulatory effects of MEK inhibition","volume":"23","author":"Dennison","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jid.2025.12.010_bib9","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s13023-019-1262-7","article-title":"EGFR inhibition for metastasized cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosa","volume":"14","author":"Diociaiuti","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jid.2025.12.010_bib10","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.immuni.2016.01.024","article-title":"MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade","volume":"44","author":"Ebert","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.jid.2025.12.010_bib11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/laban.254","article-title":"Estimation of rat mammary tumor volume using caliper and ultrasonography measurements","volume":"42","author":"Faustino-Rocha","year":"2013","journal-title":"Lab Anim (NY)"},{"key":"10.1016\/j.jid.2025.12.010_bib12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaad.2008.09.035","article-title":"Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986-2006","volume":"60","author":"Fine","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2025.12.010_bib13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10238-021-00783-z","article-title":"Selumetinib: a selective MEK1 inhibitor for solid tumor treatment","volume":"23","author":"Hedayat","year":"2023","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.jid.2025.12.010_bib14","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s13023-024-03190-1","article-title":"Therapies for cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: a systematic review of 157 cases","volume":"19","author":"Hwang","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jid.2025.12.010_bib15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/bjd\/ljad335","article-title":"MicroRNA-200b-mediated reversion of a spectrum of epithelial-to-mesenchymal transition states in recessive dystrophic epidermolysis bullosa squamous cell carcinomas","volume":"190","author":"Illmer","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2025.12.010_bib16","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.3390\/jcm14145071","article-title":"Neurofibromatosis Type 1 and MEK inhibition: a comprehensive review with focus on selumetinib therapy","volume":"14","author":"Imataka","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.jid.2025.12.010_bib17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/bs.pmbts.2024.07.011","article-title":"Drug repurposing for rare diseases","volume":"207","author":"Israr","year":"2024","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/j.jid.2025.12.010_bib18","doi-asserted-by":"crossref","first-page":"8131","DOI":"10.1007\/s00432-023-04737-8","article-title":"Cancer immune escape: the role of antigen presentation machinery","volume":"149","author":"Kallingal","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jid.2025.12.010_bib19","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2340\/00015555-2781","article-title":"Epidemiology and outcome of squamous cell carcinoma in epidermolysis bullosa in Australia and New Zealand","volume":"98","author":"Kim","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2025.12.010_bib20","doi-asserted-by":"crossref","first-page":"e1109","DOI":"10.1634\/theoncologist.2020-0069","article-title":"The use of MEK inhibitors in neurofibromatosis type 1-associated tumors and management of toxicities","volume":"25","author":"Klesse","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.jid.2025.12.010_bib21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1155\/2011\/153108","article-title":"TGF\u03b2-signaling in squamous cell carcinoma occurring in recessive dystrophic epidermolysis bullosa","volume":"34","author":"Knaup","year":"2011","journal-title":"Anal Cell Pathol (Amst)"},{"key":"10.1016\/j.jid.2025.12.010_bib22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/ph13010009","article-title":"Mitogen-activated protein kinase inhibitors and T-cell-dependent immunotherapy in cancer","volume":"13","author":"Kumar","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jid.2025.12.010_bib23","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/bjd\/ljaf205","article-title":"Efficacy and safety of rigosertib in patients with recessive dystrophic epidermolysis bullosa-associated advanced\/metastatic cutaneous squamous cell carcinoma","volume":"193","author":"Laimer","year":"2025","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2025.12.010_bib24","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jid.2021.07.170","article-title":"Transcriptomic repositioning analysis identifies mTOR inhibitor as potential therapy for epidermolysis bullosa simplex","volume":"142","author":"Lee","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2025.12.010_bib25","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jtho.2019.02.004","article-title":"The combination of MEK inhibitor with immunomodulatory antibodies targeting programmed death 1 and programmed death ligand 1 results in prolonged survival in Kras\/p53-driven lung cancer","volume":"14","author":"Lee","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jid.2025.12.010_bib26","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1002\/1097-0142(19900915)66:6<1276::AID-CNCR2820660629>3.0.CO;2-A","article-title":"Squamous cell carcinoma in epidermolysis bullosa. Treatment with systemic chemotherapy","volume":"66","author":"Lentz","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.jid.2025.12.010_bib27","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/s41419-019-2192-y","article-title":"The impact of oncogenic RAS on redox balance and implications for cancer development","volume":"10","author":"Lim","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jid.2025.12.010_bib28","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/bjd.14104","article-title":"Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: best clinical practice guidelines","volume":"174","author":"Mellerio","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2025.12.010_bib29","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13023-016-0489-9","article-title":"Inherited epidermolysis bullosa and squamous cell carcinoma: a systematic review of 117 cases","volume":"11","author":"Montaudi\u00e9","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jid.2025.12.010_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-48279-y","article-title":"Morphological and cytoskeleton changes in cells after EMT","volume":"13","author":"Nurmagambetova","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jid.2025.12.010_bib31","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.3390\/ijms20122885","article-title":"Extracellular-signal regulated kinase: a central molecule driving epithelial-mesenchymal transition in cancer","volume":"20","author":"Olea-Flores","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2025.12.010_bib32","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/exd.14481","article-title":"Transcriptomic profiling of recessive dystrophic epidermolysis bullosa wounded skin highlights drug repurposing opportunities to improve wound healing","volume":"31","author":"Onoufriadis","year":"2022","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2025.12.010_bib33","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jamadermatol.2020.0304","article-title":"Pembrolizumab for treatment of a patient with multiple cutaneous squamous cell carcinomas and recessive dystrophic epidermolysis bullosa","volume":"156","author":"Piccerillo","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2025.12.010_bib34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s40425-017-0268-8","article-title":"The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment","volume":"5","author":"Poon","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jid.2025.12.010_bib35","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s12326-024-00627-z","article-title":"Neue Lokal- und Systemtherapien bei epidermolysis bullosa","volume":"23","author":"Prodinger","year":"2024","journal-title":"Hautnah"},{"key":"10.1016\/j.jid.2025.12.010_bib36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jid.2025.12.010_bib37","article-title":"Cemiplimab-induced hyperosmolar hyperglycemic state with concurrent diabetic ketoacidosis in a patient receiving treatment for cutaneous squamous cell carcinoma","volume":"16","author":"Pyronneau","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.jid.2025.12.010_bib38","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/jdv.15835","article-title":"Combined anti-inflammatory and low-dose antiproliferative therapy for squamous cell carcinomas in recessive dystrophic epidermolysis bullosa","volume":"34","author":"Reimer","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2025.12.010_bib39","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0092-8674(75)90183-X","article-title":"Formation of a keratinizing epithelium in culture by a cloned cell line derived from a teratoma","volume":"6","author":"Rheinwald","year":"1975","journal-title":"Cell"},{"key":"10.1016\/j.jid.2025.12.010_bib40","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3875","article-title":"Cutaneous squamous cell carcinoma in epidermolysis bullosa: a 28-year retrospective study","volume":"101","author":"Robertson","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2025.12.010_bib41","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.tips.2021.01.003","article-title":"Drug repurposing for rare diseases","volume":"42","author":"Roessler","year":"2021","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jid.2025.12.010_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.humimm.2024.110805","article-title":"Unravelling drivers of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa","volume":"85","author":"Santucci","year":"2024","journal-title":"Hum Immunol"},{"key":"10.1016\/j.jid.2025.12.010_bib43","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2147\/CCID.S54681","article-title":"Dystrophic epidermolysis bullosa: a review","volume":"8","author":"Shinkuma","year":"2015","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.jid.2025.12.010_bib44","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev.immunol.021908.132706","article-title":"T cell activation","volume":"27","author":"Smith-Garvin","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jid.2025.12.010_bib45","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/j.jid.2023.05.024","article-title":"Type VII collagen deficiency in the oncogenesis of cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosa","volume":"143","author":"South","year":"2023","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2025.12.010_bib46","doi-asserted-by":"crossref","first-page":"D431","DOI":"10.1093\/nar\/gkz1023","article-title":"Lincs Data Portal 2.0: next generation access point for perturbation-response signatures","volume":"48","author":"Stathias","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jid.2025.12.010_bib47","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v103.4870","article-title":"Variable outcome of immunotherapy in advanced multiple cutaneous squamous cell carcinomas in two patients with recessive dystrophic epidermolysis bullosa","volume":"103","author":"Trefzer","year":"2023","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2025.12.010_bib48","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41590-020-00818-9","article-title":"MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects","volume":"22","author":"Verma","year":"2021","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jid.2025.12.010_bib49","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.1038\/onc.2011.180","article-title":"Integrative mRNA profiling comparing cultured primary cells with clinical samples reveals PLK1 and C20orf20 as therapeutic targets in cutaneous squamous cell carcinoma","volume":"30","author":"Watt","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.jid.2025.12.010_bib50","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/1878-0261.12017","article-title":"Epithelial-mesenchymal transition in tumor metastasis","volume":"11","author":"Yeung","year":"2017","journal-title":"Mol Oncol"},{"key":"10.1016\/j.jid.2025.12.010_bib51","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3390\/ijms23021007","article-title":"Transcriptome-guided drug repurposing for aggressive SCCs","volume":"23","author":"Zauner","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2025.12.010_bib52","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1471-2105-14-128","article-title":"Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool","volume":"14","author":"Chen","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.jid.2025.12.010_bib53","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nbt.3820","article-title":"Nextflow enables reproducible computational workflows","volume":"35","author":"Di Tommaso","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jid.2025.12.010_bib54","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41587-020-0439-x","article-title":"The nf-core framework for community-curated bioinformatics pipelines","volume":"38","author":"Ewels","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jid.2025.12.010_bib55","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-31061-w","article-title":"Evaluation of modified interferon alpha mRNA constructs for the treatment of non-melanoma skin cancer","volume":"8","author":"Hochmann","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jid.2025.12.010_bib56","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/bjd\/ljad335","article-title":"MicroRNA-200b-mediated reversion of a spectrum of epithelial-to-mesenchymal transition states in recessive dystrophic epidermolysis bullosa squamous cell carcinomas","volume":"190","author":"Illmer","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2025.12.010_bib57","doi-asserted-by":"crossref","first-page":"W90","DOI":"10.1093\/nar\/gkw377","article-title":"Enrichr: a comprehensive gene set enrichment analysis web server 2016 update","volume":"44","author":"Kuleshov","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jid.2025.12.010_bib58","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1093\/nar\/gks042","article-title":"Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation","volume":"40","author":"McCarthy","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jid.2025.12.010_bib59","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1038\/sj.jid.5700878","article-title":"Patients with recessive dystrophic epidermolysis bullosa develop squamous-cell carcinoma regardless of type VII collagen expression","volume":"127","author":"Pourreyron","year":"2007","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2025.12.010_bib60","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jid.2025.12.010_bib61","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.jid.2017.11.022","article-title":"Extracellular vesicles as biomarkers for the detection of a tumor marker gene in epidermolysis bullosa-associated squamous cell carcinoma","volume":"138","author":"Sun","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2025.12.010_bib62","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/jdv.19488","article-title":"Metformin shows anti-neoplastic properties by inhibition of oxidative phosphorylation and glycolysis in epidermolysis bullosa-associated aggressive cutaneous squamous cell carcinoma","volume":"38","author":"Welponer","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2025.12.010_bib63","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12964-020-00550-9","article-title":"A cancer stem cell-like phenotype is associated with miR-10b expression in aggressive squamous cell carcinomas","volume":"18","author":"Wimmer","year":"2020","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.jid.2025.12.010_bib64","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1002\/cpz1.90","article-title":"Gene set knowledge discovery with Enrichr","volume":"1","author":"Xie","year":"2021","journal-title":"Curr Protoc"},{"key":"10.1016\/j.jid.2025.12.010_bib65","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.3390\/cancers15133286","article-title":"Biomarker discovery in rare malignancies: development of a miRNA signature for RDEB-cSCC","volume":"15","author":"Zauner","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jid.2025.12.010_bib66","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3390\/ijms23021007","article-title":"Transcriptome-guided drug repurposing for aggressive SCCs","volume":"23","author":"Zauner","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2025.12.010_bib67","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.3390\/ijms24065197","article-title":"A novel fluorescence-based screen of gene editing molecules for junctional epidermolysis bullosa","volume":"24","author":"Zwicklhuber","year":"2023","journal-title":"Int J Mol Sci"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X25036784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X25036784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:40:11Z","timestamp":1785901211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X25036784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":67,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0022202X25036784"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2025.12.010","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transcriptome-guided drug repurposing identifies selumetinib for an aggressive epithelial cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2025.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}